Improving Cell Therapy with Artificial Membrane Binding Proteins. v1.1
Research type
Research Study
Full title
Improving Adoptive Cell Therapy for cancer with Artificial Membrane Binding Proteins
IRAS ID
290687
Contact name
David Coe
Contact email
Sponsor organisation
Cytoseek
Duration of Study in the UK
5 years, 4 months, 1 days
Research summary
Cytoseek proposes to use human tissues purchased from the NHS-BT, contract research organisations or supplied by consenting healthy donors to characterise the effect of our novel artificial membrane-binding protein (AMBP) modification on the viability, phenotype and proliferative capacity of immune cells including, but not limited to, NK cells, T cells and Dendritic Cells purified from tissues such as blood and tumour biopsies. AMBP modified immune cells will be tested for their ability to kill tumour cells as well as the secretion of tumour destructive proteins such as Interferon gamma and tumour necrosis factor alpha.
Additionally, we will genetically engineer immune cells to express proteins, such as Chimeric Antigen Receptors (CAR), that target and kill tumour cells. Targeted CAR cells are currently used for the treatment of tumours and will provide a clinically validated experimental platform to test our AMBP both in vitro and in vivo.
AMBP coated, genetically modified immune cells will be used in murine pre-clinical models of solid and blood tumours, these data will provide a mechanistic insight into how a range of carefully designed artificial membrane-binding proteins will impact immune cell dependent tumour cell killing. Multiple AMBP targets will be tested on cells and the lead candidates, the ones showing the best tumour cytotoxicity, will be selected to generate a unique therapeutic strategy that can be tested in humans trials for the prevention of cancer.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
21/EE/0182
Date of REC Opinion
27 Jul 2021
REC opinion
Further Information Favourable Opinion